Mesoblast (MESO) Shares Outstanding (2014 - 2026)
Mesoblast (MESO) posted Shares Outstanding (Entity) of $129.0 for Q4 2025, down 100.0% sequentially from $120.8 million in Q2 2025, and up 13.16% YoY from $114.0 in Q4 2024.
Analysis
Mesoblast (MESO) Shares Outstanding (2014 - 2026) Analysis & Trends
Mesoblast has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $129.0 in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 13.16% year-over-year to $129.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.0 (up 13.16% YoY) and the FY2025 annual result came in at $120.8 million, up 121999206.06% from the prior year.
- Shares Outstanding (Entity) slipped to $129.0 in Q4 2025 per MESO's latest filing, from $120.8 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $120.8 million in Q2 2025 and troughed at $60.0 in Q1 2021.
- A 5-year average of $8.1 million and a median of $74.0 in 2022 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) slumped 32.94% in 2024, then surged 121999206.06% in 2025.
- Over 5 years, Shares Outstanding (Entity) stood at $65.0 in 2021, then grew by 13.85% to $74.0 in 2022, then jumped by 129.73% to $170.0 in 2023, then plunged by 32.94% to $114.0 in 2024, then advanced by 13.16% to $129.0 in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $129.0, $120.8 million, and $114.0 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Mesoblast | 2.23 Bn | 2.13 Bn | - | 129.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 129.49 Mn |
| Dec 31, 2025 | 120.78 Mn |
| Jun 30, 2025 | 120.78 Mn |
| Dec 31, 2024 | 98.67 Mn |
| Jun 30, 2024 | 98.67 Mn |
| Dec 31, 2023 | 73.90 Mn |
| Jun 30, 2023 | 73.90 Mn |
| Mar 31, 2023 | 64.89 Mn |
| Dec 31, 2022 | 64.89 Mn |
| Sep 30, 2022 | 64.89 Mn |
| Jun 30, 2022 | 64.89 Mn |
| Mar 31, 2022 | 60.51 Mn |
| Dec 31, 2021 | 60.51 Mn |
| Sep 30, 2021 | 60.51 Mn |
| Jun 30, 2021 | 60.51 Mn |
| Mar 31, 2021 | 52.88 Mn |
| Dec 31, 2020 | 52.88 Mn |
| Sep 30, 2020 | 52.88 Mn |
| Jun 30, 2020 | 52.88 Mn |
| Mar 31, 2020 | 49.44 Mn |